Pharma News

Zilovertamab vedotin by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zilovertamab vedotin overview

Zilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), non-squamous non-small-cell lung cancer, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, or Richter transformation lymphoma, Burkitt lymphoma, lymphoplasmacytoid lymphoma, Waldenström macroglobulinemia, T-cell non-Hodgkin lymphoma, acute lymphoid leukemia, or acute myeloid leukemia, estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, or human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), ovarian cancer and pancreatic cancer. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE.

Merck overview

Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

For a complete picture of Zilovertamab vedotin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 4 December 2023

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.




Source link
#Zilovertamab #vedotin #Merck #NonSmall #Cell #Lung #Cancer #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *